NFL Biosciences’ ambition is to develop the first oral medication based on kudzu extracts to combat excessive alcohol consumption. NFL-301 will differentiate itself from other kudzu-based dietary supplements, in particular through its positioning as a drug that complies with Marketing Authorization (MA) regulations, and its quality control in line with good pharmaceutical practice.

NFL Biosciences filed a patent application for NFL-301 in July 2023. It aims to protect sustained-release formulations of kudzu extracts, a plant derived from traditional Chinese medicine, and their uses in the treatment of alcohol reduction.

NFL Biosciences and its industrial partner Athena Pharmaceutiques have developed a sustained-release form of kudzu extract in the form of microgranules, NFL-301. This innovation offers a prolonged effect, ease of administration and adaptability of dosage compared with capsules or tablets.

In May 2024, NFL Biosciences received feedback from the FDA on the development plan covering manufacturing methods, preclinical studies, and clinical trials for the NFL-301 product. NFL Biosciences plans to implement the NFL-301 development plan in accordance with the FDA’s expectations.